The Antimicrobial Memory Recovery & Exploratory Programme aims to recover the knowledge, data, and assets of forgotten, abandoned, or withdrawn antibiotics while the search for new classes is pursued, and a new generation of researchers in antibiotic R&D is championed.

Antibiotics for children have often not been developed for the needs of children. GARDP’s paediatric antibiotic programme aims to expedite the development of new, improved and adapted antibiotics to treat serious bacterial infections in children of-all-ages. Approaches include, for example, dose improvement the, change of the duration of treatment and / or the formulation of the medication.

A significant sexually transmitted infection (STI), Neisseria gonorrhoeae is threatening to soon become untreatable due to its resistance to all available classes of antimicrobials. This programme is designed to accelerate the entry of new antibiotics for the treatment of gonorrhea and to investigate the use of novel drug combinations.

The GARDP neonatal sepsis programme aims to provide an evidence base for the use of antibiotics, both old and new, in neonates with serious bacterial infections (SBIs), as the currently available standard of care in many countries is increasingly becoming less effective due to antimicrobial resistance. One of the long-term goals is the clinical development of formulations that are especially adapted for use in neonates.